Heterotransplantation of cell lines derived from human malignant neoplasms into golden hamsters treated with antithymocyte serum
- PMID: 1085379
Heterotransplantation of cell lines derived from human malignant neoplasms into golden hamsters treated with antithymocyte serum
Abstract
Thirteen cell lines of tissue culture originated from human malignant neoplasms were transplanted into cheek pouches of adult golden hamsters treated with anti-hamster thymocyte serum. In eleven cell lines, transplantation tests with 3.5 X 10(6) to 6.8 X 10(6) cells resulted in neoplastic growth within 4 weeks. In other two cell lines including one from neuroblastoma and another from Burkitt's lymphoma, the inoculum size had to be raised to 11.8 X 10(6) and 12.2 X 10(6) cells to get tumor growth, respectively. The histological appearance of those tumors was consistent with that of the individual primary neoplasms despite of their long in vitro histories. Anaplasia grading of the tumors appeared not to be correlated with the frequency of take.
Similar articles
-
The hamster as a host for the growth and study of human tumor cell populations.Cancer Res. 1974 May;34(5):958-63. Cancer Res. 1974. PMID: 4545096 No abstract available.
-
Carcinogenesis in tissue culture 27: heterotransplantation as an alternative in vivo assay for neoplastic state of cells in culture.Jpn J Exp Med. 1976 Aug;46(4):457-62. Jpn J Exp Med. 1976. PMID: 1086916
-
Serial transplantation of Burkitt's tumor (EB3) cells in newborn Syrian hamsters and its facilitation by antilymphocyte serum.Cancer Res. 1970 Feb;30(2):338-45. Cancer Res. 1970. PMID: 4917979 No abstract available.
-
[Effect of antilymphocyte serum on tumor growth (literature survey)].Zh Mikrobiol Epidemiol Immunobiol. 1972 Mar;49(3):93-7. Zh Mikrobiol Epidemiol Immunobiol. 1972. PMID: 4553064 Review. Russian. No abstract available.
-
Spontaneous regression of cancer.Prog Clin Cancer. 1967;3:79-95. Prog Clin Cancer. 1967. PMID: 4867093 Review. No abstract available.
Cited by
-
Syrian hamster as an ideal animal model for evaluation of cancer immunotherapy.Front Immunol. 2023 Feb 27;14:1126969. doi: 10.3389/fimmu.2023.1126969. eCollection 2023. Front Immunol. 2023. PMID: 36923404 Free PMC article. Review.